Thalidomide-O-C3-acid

Background Introduction

Thalidomide-O-C3-acid is a specialized E3 ligase ligand-linker conjugate, designed for use in PROTAC (Proteolysis Targeting Chimera) technology. This molecule combines a thalidomide-based CRBN (Cereblon) ligand with a short, three-carbon linker terminating in a carboxylic acid group, making it ideal for further chemical conjugation. By serving as a modular building block, Thalidomide-O-C3-acid facilitates the development of next-generation targeted protein degraders.

Mechanism

The mechanism of Thalidomide-O-C3-acid centers on targeted protein degradation via the ubiquitin-proteasome system. The thalidomide moiety specifically binds to the CRBN E3 ubiquitin ligase, while the carboxylic acid terminus enables straightforward coupling to target protein ligands (warheads). When incorporated into a PROTAC, this conjugate mediates the close proximity of CRBN to the protein of interest, promoting ubiquitination and subsequent proteasomal degradation.

Applications

Thalidomide-O-C3-acid is extensively used in drug discovery, particularly in the synthesis of custom PROTAC molecules for targeted protein degradation studies. It is suitable for developing PROTACs aimed at CRBN-recruiting for various disease-related target proteins. Researchers utilize this conjugate to accelerate the production of novel protein degraders in oncology, neurodegeneration, and other therapeutic areas where selective protein knockdown is desirable. Its modular design and proven CRBN-binding efficiency make Thalidomide-O-C3-acid an essential tool in chemical biology and medicinal chemistry.

The Thalidomide-O-C3-acid E3 Ligase Ligand-Linker Conjugate plays a crucial role in the development of PROTACs by facilitating targeted protein degradation through its unique structural components. This molecule integrates a strategically designed linker, a specific ligand, and a reactive site that together enhance the efficiency and specificity of protein degradation.

Linker: The linker in this molecule is a three-carbon (C3) chain, providing moderate flexibility that balances stability and adaptability. Its non-cleavable nature ensures sustained interaction with the E3 ligase, optimizing the degradation process by maintaining a stable connection between the ligand and the target protein.

Ligand: The ligand component is derived from thalidomide, characterized by its glutarimide moiety, which effectively recruits the CRBN E3 ligase. This structural feature enhances the specificity of the conjugate, ensuring selective binding and degradation of the target protein.

Reactive Site: The reactive site of the Thalidomide-O-C3-acid is an acid functional group, which is ideal for coupling with amine-containing target protein ligands. This site supports amide bond formation, a robust and reliable reaction type, facilitating stable conjugate formation.

Recommended Target Protein Ligand: The recommended warhead for this molecule is an amine-containing ligand, which benefits from forming stable amide bonds with the reactive site. This compatibility allows for precise targeting of proteins with exposed lysine residues, making it suitable for applications in investigating protein function and validating therapeutic targets in proteomics research.